Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Four-year results of riboflavin ultraviolet-A corneal collagen cross-linking for progressive corneal ectasia in 129 eyes

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cross-linking

Session Date/Time: Sunday 11/09/2016 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 3

First Author: : S.AL Zaid SAUDI ARABIA

Co Author(s): :    S. Al Swailem              

Abstract Details


To report the clinical course of conventional corneal collagen cross-linking (CXL) with up to 4.7 years of follow-up, for the treatment of progressive corneal ectasia.


Anterior segment division, King Khalid eye Specialist Hospital, Saudi Arabia.


The records of 129 eyes (keratoconus = 114; post-excimer ectasia=15) which underwent CXL using Dresden’s protocol, were reviewed retrospectively. At the baseline and all follow-up examinations, Snellen uncorrected visual acuity (UCVA), Snellen best corrected visual acuity (BCVA), simulated mean keratometry(Sim K) reading, central corneal thickness (CCT), and complications were analysed.


The mean age of the 83 men and 46 women was 24.73± 5.5 (range 14-42) years, and 68.2% were in the age range of 21-30 years. The CCT almost resumed its baseline reading at 9-months postoperatively (460.5 vs. 479.7um), and stabilized thereafter (465.3um) (p<0.086). At last follow-up, median Sim K decreased from 45.1±3.6D (range 37.9-66.9D) to 44.5±3.6D(range 37.6-60.5D) (p<0.008). At last follow-up, median UCVA and BCVA changed from 20/60 to 20/40 and 20/25 to 20/25, respectively. The UCVA of ≥20/40 was recorded in 38.8% and 53.3% before and after CXL, respectively. At last follow-up, mean UCVA improved and worsened by ≥ 1 Snellen line in 27.1% and 10.8%, respectively. Complications included: transient corneal haze(n=9) and sterile infiltrate(n=3).


Our study not only demonstrated a halt in ectasia progression, but also showed a significant improvement in visual acuity at 4-year of follow-up. Conventional CXL is safe in stabilization of progressive ectasia. Given the simplicities, minimal costs of CXL and likelihood of reducing the need of keratoplasty, it might also be well-suited for developing countries.

Financial Disclosure:


Back to previous